PRFX
PRF Technologies Ltd. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
Price History
Fundamentals
| Market Cap | $4.14M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.11 |
| EPS (TTM) | $-7.47 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -90.37% |
| Debt/Equity | 0.23 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 46.7 |
| Beta | 0.98 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $17.95 |
| 52-Week Low | $1.28 |
| 50-Day Avg | $1.77 |
| 200-Day Avg | $3.70 |
| Avg Volume | $3.05M |
| Volume | 109.0K |
Performance Analysis
NEUTRALPRFX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report